Home » Stocks » OTLC

Oncotelic Therapeutics, Inc. (OTLC)

Stock Price: $0.2650 USD -0.0050 (-1.85%)
Updated Apr 16, 2021 3:55 PM EDT - Market closed
Market Cap 23.74M
Revenue (ttm) 1.74M
Net Income (ttm) -9.50M
Shares Out 89.60M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $0.2650
Previous Close $0.2700
Change ($) -0.0050
Change (%) -1.85%
Day's Open 0.2700
Day's Range 0.2600 - 0.3050
Day's Volume 198,542
52-Week Range 0.1300 - 0.3800

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AGOURA HILLS, California, March 15, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the regulatory approval from the Ministry of Food and Drug Safety of Korea for the phas...

Other stocks mentioned: MATN
1 month ago - GlobeNewsWire

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT

Other stocks mentioned: MATN
1 month ago - GlobeNewsWire

AGOURA HILLS, California, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respirato...

Other stocks mentioned: MATN
1 month ago - GlobeNewsWire

AGOURA HILLS, California, Feb. 16, 2021 (GLOBE NEWSWIRE) --  Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious disease and respirat...

Other stocks mentioned: MATN
2 months ago - GlobeNewsWire

AGOURA HILLS, California, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced t...

Other stocks mentioned: MATN
2 months ago - GlobeNewsWire

AGOURA HILLS, California, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announce to...

Other stocks mentioned: MATN
2 months ago - GlobeNewsWire

AGOURA HILLS, California, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and infectious diseases, announced t...

Other stocks mentioned: MATN
2 months ago - GlobeNewsWire

AGOURA HILLS, California, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, reported positive int...

Other stocks mentioned: MATN
3 months ago - GlobeNewsWire

AGOURA HILLS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today that it has enrolled and treated its first sentinel Part 1 pati...

Other stocks mentioned: MATN
3 months ago - GlobeNewsWire

About OTLC

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the tre... [Read more...]

Industry
Biotechnology
IPO Date
Aug 26, 1993
Stock Exchange
OTCMKTS
Ticker Symbol
OTLC
Full Company Profile

Financial Performance

Financial Statements